Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu ASK Pharma Postpones ChiNext IPO

publication date: Jan 13, 2014
Jiangsu Aosaikang Pharmaceutical has temporarily delayed its imminent IPO, after the price was set. The transaction was scheduled to raise 4 billion RMB ($669 million), which would have made it the largest IPO ever for the ChiNext exchange. According to the company, it postponed the IPO because the offering was “relatively large,” though regulators may have forced the move. The transaction was priced at 67 times trailing earnings, against a ChiNext average of 55. The dramatic delay is a setback for China’s new IPO rules – no matter who decided to put Aosaikang’s debut on hold. More details....

Stock Symbol: (SHE: 300361)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital